Development of a Test that Measures Real-Time HER2 Signaling Function in Live Breast Cancer Cell Lines and Primary Cells

Measurement of HER2 signaling activity in the tumor cells of patients with breast cancer is a feasible approach to explore as a biomarker to identify HER2-driven cancers not currently diagnosable with genomic techniques.

 BMC Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.